Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms in Women with Breast Cancer

Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms in Women with Breast Cancer - Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027481

Enrollment

Registered

2017-05-25

Start date

2017-05-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Oral treatment of Sokei-Kakketsu-To(TJ-53) for 3 months Joint exercises

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast cancer patients treated with Aromatase inhibitor(any of Aromatase Inhibitors: Letrozole, Anastrozole and Exemestane) who developed joint symptoms or worsend the symptoms

Exclusion criteria

Exclusion criteria: 1. Patients having neurological disorder, collagen disease and orthopedic disease who show the similar joint symptoms. 2. Patients treated with medicine that may affect the joint symptoms (NSAIDs, Acetaminophen or Opioids etc.)

Design outcomes

Primary

Measure	Time frame
Effectiveness in the treatment of TJ-53 to the aromatase inhibitor associated joint symptoms at 3 months. HAQ-DI (Health Assessment Questionnaire-Disability Index) will be used for the assessment of the effectiveness.	—

Countries

Japan

Contacts

Public ContactShinji Ozaki

National Hospital Organization Kure Medical Center/Chugoku Cancer Center Department of Breast Surgery

ozakis@kure-nh.go.jp0823-22-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026